Pleco Therapeutics

Pleco Therapeutics receives FDA Orphan Drug Designation

16th January 2024 – Nijmegen, The Netherlands – The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to Pleco Therapeutics BV’s lead compound, PTX-252 for the treatment of Acute Myeloid Leukaemia (AML). PTX-252 is a novel molecular entity developed to increase the sensitivity of cancer cells to chemotherapy. The FDA’s designation acknowledges the...
Pleco Therapeutics BV Jonkerbosplein 52 6534 AB Nijmegen The Netherlands

+31 611 325 510